

PERSONAL INFORMATION

Felice Alfonso Nava



 Via Pietro Cossa, 10 – 35124 Padova
 +39-347-6188139
 felice.nava@icloud.com
 felicealfonso.nava.grpp@pd.omceo.it (certified e-mail)
 www.felice-nava.it

Sex M | Date of birth 07/March/1967 | Nationality Italian

POSITION

- Director Penitentiary Medicine and Drug Abuse Unit – Public Health Unit n. 6 Euganea – Padua (full time)
 - Medical Manger Mental health and penitentiary medicine – Veneto Region (2 times per week)

WORK EXPERIENCE

- From 15 Oct 2012 **Director Penitentiary Medicine and Drug Abuse Service (Ser.D.)**
 Discipline Clinical Pharmacology and Toxicology
 Public Health Unit n. 6 Euganea – Via Scrovegni 14 - 35131 Padua, Italy

 - Director of a clinical unit for penitentiary medicine and for drug abuse services (full time)

Business or sector Public health system

- From 01 Feb 2018 **Medical manager Mental health and penitentiary medicine – Regional health organization – Veneto Region**
 Palazzo Molin – San Polo 25124 – 30125 Venice, Italy

 - Medical manager at the Regional health organization in the area of penitentiary medicine (2 times per week)

Business or sector Veneto Region

- From 19 Sept 2003 – to 14 Oct 2012 **Medical doctor at Drug Abuse Service (Ser.D.) – Department of Addiction Medicine**
 Discipline Clinical Pharmacology and Toxicology
 Public Health Unit n. 8 Asolo – Via Forestuzzo 4 – 30125 Asolo (Treviso), Italy

 - Health care provider for drug users also with dual diagnosis and/or correlated pathologies

Business or sector Public health system

- From 01 Nov 2002 – to 18 Sept 2003 **Medical doctor at Drug Abuse Unit (Ser.D.) – Department of Addiction Medicine**
 Discipline Clinical Pharmacology and Toxicology
 Public Health Unit at Brescia – Viale Duca degli Abruzzi 15 – 25122 Brescia, Italy

 - Health care provider for drug users also with dual diagnosis and/or correlated pathologies

Business or sector Public health system

- From 03 Sept 2001 – to 30 nov 2002 **Medical doctor at Drug Abuse Unit (Ser.D.) – Department of Addiction Medicine**
 Discipline Clinical Pharmacology and Toxicology
 Public Health Unit at Varese – Via Ottorino Rossi 9 – 21110 Varese, Italy

 - Health care provider for drug users also with dual diagnosis and/or correlated pathologies

Business or sector Public health system

EDUCATION AND TRAINING

- 2019-2020 **Advanced course in management of complex health units**
 University of Ferrara, Department of Management and Economy, Via Voltapaletto 11, 44121 Ferrara, Italy
 ▪ Accredited from Emilia-Romagna Region under the laws D.Lgs. 502/92 (art. 15 and 16-quinquies) and DPR 484/97 (art. 7)
- 2003-2007 **Specialist in Psychotherapy**
 ASISPE specialization school (accredited school from Italian Ministry of Education under the law D.M. 24/10/94), Via Settembrini 2 – 20124 Milano
 ▪ Acquired expertise in cognitive-behavioural psychotherapy
- 1998-2003 **PhD in Neuroscience**
 University of Cagliari – Via Università 40 – 09124 Cagliari, Italy
 ▪ Acquired expertise and research activities in the field of neuropsychopharmacology, neurobiology and psychopharmacology of substances of abuse
- 1994-1998 **Specialist in Toxicology (Pharmacology and Clinical Toxicology)**
 University of Messina – Piazza Pugliatti 1 – 98122 Messina
 ▪ Acquired expertise and skills in the field of experimental and clinical pharmacology and toxicology
- 1985-1994 **Doctor of Medicine**
 University of Reggio Calabria at Catanzaro – Viale Europa – 88100 Catanzaro, Italy
 ▪ Acquired expertise and skills to obtaining the medical license
- 1980-1985 **Scientific diploma**
 Scientific high school “Luigi Siciliani”– Via Alessandro turco 7 – 88100 Catanzaro, Italy
 ▪ Acquired knowledges on scientific and humanities fields

PERSONAL SKILLS

Mother tongue Italian

Other language

	UNDERSTANDING		SPEAKING		WRITING
	Listening	Reading	Spoken interaction	Spoken production	
English	B2	B2	B2	B2	C1

Proficiency attested by Department of Linguistics, University of Calabria

Communication skills

Assertive and effective communication skills, capacity of negotiation and conflict management developed tin the multidisciplinary work done also as team leader. The above skills have been developed in the fields of clinical research, teaching and clinical activity (in the public health service) with some significant international experiences. Knowledge and familiarity of the multidisciplinary and international contexts and skills in inter-personal relationship and cooperation.

Organizational / managerial skills

Ability to organize the research and clinical work for projects also in international and complex contexts. As director of clinical unit has promoted the innovation and team working using motivational, incentive, coaching, controlling, and budgeting techniques. The above skills have been developed as director of a clinical unit which includes 63 people and has got an annual budget of about 2 millions of euros and as medical regional manager in the field of health planning with an expert management group and an annual budget of about 7 millions di euros.

Job-related skills	<p>Elevated clinical expertise in the fields of drug addiction, pharmacology, correlated pathologies (infection and psychiatric diseases), health in prison and public health developed in the work activity inside the Drug abuse services (Ser.D), in the health prison services, and in the public health system. The above skills are proven by the good results reached in the clinical, organizational, and health planning.</p> <p>Skills in the management of personnel, controlling system, and budgeting developed as director of clinical unit and regional medical manger.</p> <p>Skills in the health planning both at regional and national level with the production of clinical procedures, address lines, therapeutic diagnostic paths, guidelines in the field of drug addiction and public health (e.g. HCV national and regional elimination plans, harm reduction actions, COVID-19 management inside prisons). At national and regional levels is part of institutional teams in the fields of addiction medicine, psychiatry, co-morbidities, health in prison and public health.</p> <p>Teaching and mentoring in degree and specializing courses in the field of pharmacology and neurobiology of substance of abuse (at Universities of Padua, Modena and Reggio Emilia, Institute of Cognitive Therapy of Padua, Catholic University of Milan). Experience as trainer and supervisor of clinical groups.</p>
Computer skills	Good command of Microsoft Office™ and Mac tools
Driving license	Driving license for car and motorcycle

ADDITIONAL INFORMATION

	Teaching activity
AY 2013-14	University of Padova – Degree in Obstetrics, seminary: “Pharmacology of substance of abuse in pregnancy” 4h, 12 Dec 2013
AY 2014-15	University of Padova – Degree in Obstetrics, seminary: “Pharmacology of substance of abuse in pregnancy” 4 h, 4 Dec. 2014 University of Padova – Advanced course in “Pharmacy and Clinical Pharmacology”, seminary: “Pharmacotherapy of addiction” 1h, 21 March 2015
AY 2015-16	University of Padova – Degree in Obstetrics, seminary: “Pharmacology of substance of abuse in pregnancy” 4 h, 3 Dec 2015 ITCC Padova – Specializing School in Psychotherapy (recognized MURST), “Psychotherapy of addiction treatment” 8 h, 14 Jan 2016
AY 2016-17	University of Padova – Advanced course in “Pharmacy and Clinical Pharmacology”, “Pharmacotherapy of addiction” 1 h, 25 Jun 2016 University of Modena e Reggio Emilia - Master “Prevention and management of drug and alcohol correlates problems”, “Alcohol and prison” 3 h, 10 Feb 2017 ITCC Padova – Specializing school in Psychotherapy (recognized MURST), “Psychotherapy of addiction treatment” 8 h, 28 Sept 2017 Co.Ge.S. (Catholic University of Rome and Istituto Progetto Uomo) - Master Addiction e Risk Behavior, Mestre (Venezia), “Prison and addiction”, “Psychotherapy of cocaine addiction” 4.30 h, 13 Oct 2017 University of Padova – Degree in nursing sciences, seminary “Neurobiology and pharmacotherapy of addiction” 4 h, 8 Nov 2017
AY 2017-18	University of Padova – Advanced course in “Safe manager and contrast to mafia”, Department of Philosophy, Sociology, Pedagogy and Applied Psychology, “Psychiatric services in prisons and in community” 2 h, 11 Nov 2017 ITCC Padova – Specializing school in Psychotherapy (recognized MURST), “Psychotherapy of addiction” 8 h, 15 March 2018 Catholic University of Milan – Master in “Addiction Medicine and Drug Abuse Behavior”, Department of Psychology, “Epidemiology of drug abuse worldwide” 3 h, 24 March 2018 University of Modena e Reggio Emilia - Master Master “Prevention and management of drug and alcohol correlates problems”, “Alcohol and prison” 4 h, 12 May 2018 University of Padova – Degree in nursing sciences, seminary “Neurobiology and pharmacotherapy of addiction”, 4 h, 23 Nov 2018
AY 2018-19	University of Padova - Degree in nursing sciences, seminary “Neurobiology and pharmacotherapy of addiction” 4 h, 13 Dec 2019 University of Modena e Reggio Emilia - Master “Prevention and management of drug and alcohol correlates problems”, “Alcohol and prison” 3 h, 18 Jan 2020

Research projects	<p>Clinical research experience in the field of addiction medicine, health in prison and public health. As principal investigator or investigator has conducted several clinical researches. The most important of them are:</p> <ul style="list-style-type: none"> - Observational study of the use and misuse of sodium oxybate (GUM study – GHB Use and Misuse), promoted by FeDerSerD, 2010 - Observational and multicentric study in the SerD of the efficacy and safety of acamprosate (ACAM study), promoted FeDeSerD, 2011 - Phase III study, multicentric for the evaluation of efficacy and safety of Lofexidine (0.3. mg (Dimatex) for the treatment of opioid withdrawal syndrome (Detox study), promoted by FeDerSerD and Laboratorio CT Sanremo, 2012 - Survey on misuse and diversion in the SerD (Demos Study), promoted by Eurisko and FeDerSerD, 2012 - CCM Project “Health promoter in prison” (DDR n. 211 del 30.12.13), 2013 - CCM 2 Project “ Health intervention in prison” (DDR n. 183 del 12.12.13), 2013 - “Health with no borders” Epidemiology survey of HIV infection in prisons (in collaboration with Italian society of Penitentiary Medicine), 2013 - Prevention of the risk of infection diseases in detainees (Pride project), European Commission, 2013 - Pet therapy project – Rehab for detainees drug users (in collaboration with Istituto Zooprofilattico delle Venezie, 2015 - Research project “The crime risk evaluation in mafia detainees” (nota DAP prot. N. 353697 del 22.10.15), 2015 - Research project “The risk of relapse in sex offenders detainees” (nota DAP prot. N. 353697 del 22.10.15), 2015 - IRIDE Project – Harm reduction interventions following the international guidelines (nota DAP prot. n. 8742 del 11.03.2016), 2016 - Screening, care, diagnosis, and holistic intervention for the treatment of HCV drug users: a pilot and multicentric study inside SerD (SCUDO Project), promoted by FeDerSerD, 2017 - CORIS Project, Veneto Region “Test & Treat project: a point of care model for the HCV treatment in special population”, 2018 - Survey for HCV treatment of drug users inside SerD, promoted da Think Thank, 2018 - Survey ALT (Alcohol Test) for the alcoholic patients inside SerDs, promoted by FeDerSerD, 2020
Assessment and psychometric scales	<ul style="list-style-type: none"> - ODAS questionnaire (EADO) Scale for adequacy of daily methadone and buprenorphine dose – Author for Italian validation (Bignamini et al., 2008, Mission, 32: 15-26; Lucchini et al., 2010, Mission, 32: 15-26) - European questionnaire on Drug use among people living in prison (EQDP), 2017 – Author https://www.emcdda.europa.eu/publications/technical-reports/european-questionnaire-drug-use-among-prisoners-eqdp_en - HCV.20 V3 – Assessing risk of violence – Author for Italian validation (Douglas et al., 2019, Hogrefe Editore)
Courses and activities as visiting scientist	<ul style="list-style-type: none"> - Course “Cell culture for neuroscience”, University of Bristol, UK, 11-16 Maggio 2017 - Course “Clinical trials and critical evaluation of clinical research”, Karolinska Institute, Stockholm, 15-26 March 1999 - Summer school “Cognition, emotion, autonomic responses: the integrative role of the prefrontal cortex and limbic structures”, Netherlands Institute for Brain Research, Amsterdam, 23-27 August 1999 - Visiting scientist al National Institute of Drug Abuse, Bethesda, USA, 11-14 December 2006
Scholarship	<ul style="list-style-type: none"> - International scholarship of Italian Research Counseling (CNR) (Bando n. 203.04.20 of 11/06/98) - International scholarship of the Italian Society of Pharmacology (SIF) (01/02/99)
Experiences aboard	<ul style="list-style-type: none"> - University of California at Irvine, College of Medicine, Department of Pharmacology, Med Surge II, Irvine, CA92697-462, USA, 1999-2000

Consultant in the Institutional field

Consultant for Justice courts. At Institutional level consultant in the field in addiction medicine, in penitentiary medicine and in public health (House of representatives, Senate, Department of Drug Polices at Presidency of the council of ministers, Ministry of Health, Ministry of Justice, European Monitoring Centre Drug and Drug Addiction, Union Nations Office on Drug Control and Crime).

He is/has been member of the following Institutional groups:

At national level:

- Working group on prevention of correlates pathologies at Department of antidrug policies (DPA) at Presidency of the council of ministers (2009)
- Member of "general states" for the penal execution at Ministry of Justice – group "health and psychiatric problems in prison" (2016)
https://www.giustizia.it/giustizia/it/mg_2_19_1_10.page?previousPage=mg_2_19_1
- Coordinator of the inter-regional working group "Penitentiary Medicine" at Health commission (Presidency of council of minister – Department of Regional Affairs nota prot. n. DAR 0009369 P-4.372.0 of 13.06.19) (*current*)
- Member of the permanent inter-institutional working group for the health in prison at Presidency of the council of ministers (Health Commission prot. n. 490/DES-58SAN of 25.01.19) (*current*)
- Member of the inter-ministerial working group for COVID-19 emergency in prison (DM Ministry of Health of 21.04.20)
- Member of the working group at Ministry of Health for HCV screening (Decree of the General Director of the Prevention Sector of the Ministry of Health of 19.09.20) (*current*)

At regional level:

- Member of the inter-institutional working group for the suicide prevention in prison (with the role of coordinator) (DDR n. 104 of 05.09.18) (*current*)
- Member of the inter-institutional working group of the management of the patients with security measures (DDR n. 103 of 05.09.18) (*current*)
- Member of the regional working group of HCV elimination plan in Veneto (DGR n. 791 of 08.06.20) (*current*)
- Member of the regional commission for prevention of HIV and AIDS (DDR n. 103 of 05.09.18) (*current*)
- Member of the technical commission of the Venetian School of Public Health for the training courses for the prevention and treatment of HIV/AIDS (DGR n. 1002 del 12.07.19) (*current*)
- Member of the working group for the clinical protocol for the management of the drug abusers with psychiatric co-morbidities (vice-coordinator) (DDR n. 122 of 06.11.19)
- Member of the inter-institutional group for the implementation of probation measures for detainees with psychiatric problems (coordinator) (DDR n. 143 of 12.12.19) (*current*)
- Member of the inter-institutional group for the implementation of probation measures for detainees drug users (coordinator) (DDR n. 144 of 18.12.19) (*current*)
- Member of Veneto region "observatory for penitentiary medicine" (with the role of vicar of the President) (DGR n. 751 of 16.06.20) (*current*)
- Member of the working group for the determination of the needs and standard for residential structures for the patients with dual diagnosis (DDR n. 96 of 16.09.20) (*current*)
- Member of the working group for the revision of the standard and organization of the Penitentiary medicine in Veneto (coordinator) (DDR n. 96 del 16.09.20) (*current*)

At local level

- Member of Hospital Infection Diseases Committee (CIO) at Local Public Health Padua (Delibera del DG n. 1447 del 05.12.14)

Clinical procedure, clinical
address lines, therapeutic
diagnostic paths, State-Regions
Agreement

Contributed to the drafting of the following clinical documents:

At national level:

- Report of "General States" of penal execution – Working group n. 10 – Health and Psychiatric problems in prison" (2016)
https://www.giustizia.it/resources/cms/documents/sgep_tavolo10_relazione.pdf
- Clinical address lines for the management of COVID-19 in prisons (Conference of the Regions prot. n. 6199/C/SAN of 07.08.20)
- State-Regions agreement "Address lines for the prevention and control of COVID-19 in the residential structures and in prisons for young offenders" (Rep. N. 80/CU of 09.07.20)

At regional level:

- Preliminary project for a section of attenuated custody for detainees drug users in the Padua prison (DGR n. 436 of 04.04.14)
- Address lines for the prescription, supplying, and distribution of the drugs inside Prisons (DDR n. 82 of 08.04.15)
- Address lines for the recommendations of the Ministry of Health for the drug management (DDR n. 292 of 07.10.15)
- Project for the "interned people at risk for crime relapse" for a "work house" at Padua prison (DGR n. 1906 of 23.12.15)
- Memorandum between Veneto Region and Ministry of Health for the health management in prison (DGR n. 554 del 30.04.18)
- Address lines for the prevention of suicide in young offenders (DGR n. 1018 del 17.07.18)
- Address lines for the prevention of suicide in adult offenders (DGR n. 1019 of 17.07.18)
- Revision of the project for a section of attenuated custody in the Padua prison (DGR n. 702 of 28.05.20)
- Address lines for the management of dual diagnosed patients in Veneto Region (DDR n. 96 of 16.09.20)

At local level:

- Procedures for the management of drug users in Padua prisons (Resolution of the General Director n. 1011 of 22.11.13)
- Procedures of the control of tuberculosis in prison (Resolution of the general manager n. 773 of 12.09.13)
- Address lines for the management of hunger and thirst strike in the detainees (prot. n. 56795 del 05.08.13)
- Address lines for the management of therapy strike
- Address lines for the management of "visual surveillance" in prison (prot. . 85242 of 2013)
- Address lines for the management of emergencies in Padua prisons (prot. n. 82502 del 31.10.14)
- Procedures for the management of Ebola virus (prot. n. 52310 of 08.07.14)
- White book of penitentiary medicine in Padua (prot. n. 52310 of 08.07.14)
- Internal procedures for the management of drugs in Padua prisons (prot. n. 107179 del 24.12.15)
- Procedures for the prevention of suicide in prison (prot. n. 102314 del 07.12.15)
- Procedures for the early treatment of the new entry detainees (prot. n. 98931 of 22.12.16)
- Procedures for the so-called "special surveillance" (prot. n. 3248 of 15.01.16)
- Activation of the operative clinical files for the penitentiary medicine in Padua (prot. n. 86542 del 07.11.16 e prot. n. 86543 del 07.11.16)
- Internal procedures for the management of hunger and thirst strike (prot. n. 98933 of 22.12.16)
- Internal procedures for the "drug therapy tracing and monitoring", "best management of clinical records", "management of narcotic drugs" (prot. n. 227231 del 22.12.17)
- Procedures for the management of HCV positive patients (prot. n. 227231 del 22.12.17)
- Address lines for the improvement of drug risk management (prot. n. 184780 of 12.11.18)
- Management of the patients with chronic diseases: development of the clinical network (prot. n. 192843 of 26.11.18)
- Throughcare and clinical network with community and hospital (prot. n. 209989 of 27.12.18)
- Epidemiological collection data of HCV in detainees population and address lines for the screening (prot. n. 184792 of 12.11.18)
- Address lines for the treatment of HCV (prot. n. 184792 of 12.11.18)
- Address lines for the improvement of probation measures in drug users detainees (prot. n. 170413 of 16.10.18)
- Organizational wellbeing: prevention of burn-out in health personnel working in prison (prot. n. 209989 of 27.12.18)
- Procedures for the management of chronic patients (prot. n. 151318 of 27.09.19)
- Procedures for the management of HCV positive patients (prot. n. 151314 of 27.09.19)
- Procedures for the management of throughcare (prot. n. 151321 of 27.09.19)
- Procedures for the management of pharmacological risk (prot. n. 151317 of 27.09.19)

Editorial activity Editorial board of national and international journals (ISRN Pharmacology, International Scholarly Research Notice, Journal of Addiction, Frontiers in Addictive Disorders, Recent Patent on CNS Drug Discovery, Newsletter dell'Alcolismo, Mission, Collana Clinica delle Dipendenze e dei Comportamenti d'Abuso, Franco Angeli Editore)

Referee of several international peer-reviewed journal (European Journal of Pharmacology, Life Science, Neurobiology of Learning and Memory, Therapeutic and Chemical Risk Management, The American Journal of Drug and Alcohol Abuse, Psychopharmacology, International Environment Research Public Health, ISRN Pharmacology, Psychoendocrinology, Archives General Psychiatry, Journal of Addiction Medicine, Journal of Addiction, International Archives of Addiction research and Medicine, Drug and alcohol dependence, International Journal of STD & AIDS, Frontiers in Psychiatry)

Referee and report contributor of the European Monitoring Centre and Drug Addiction (EMCDDA) of Lisbon

Membership in scientific societies

- European Neuroscience Association (ENA)
- Italian Society of Pharmacology (SIF)
- Italian Society of Toxicology (SIT)
- Italian Society of Neuroscience (SINS)
- Italian society of Penitentiary Medicine (SIMSPE)
- Italian Federation of Professionals of Drug Abuse Services (FeDerSerD)

Member of scientific boards Scientific director of the Italian Federation of professionals of Drug abuse services (FeDerSerD)

Congress and seminars Participated at 251 congress and seminar also at international level. Invited speakers at 194 congresses

Overall contribution to science ORCID ID: <https://orcid.org/0000-0002-3103-0355>
Research ID: K-3920-2016
Scopus Author ID: 7005939086

Citations 2.105; H-index 23 (source Scopus at 16.10.20)

Publication list of the international papers peer-reviewed

Pubblicazioni **Articles in international journal peer-reviewed**

1. De Sarro G.B., Renne S., **Nava F.**, De Sarro A., 1994. Fenbufen pretreatment potentiates the anticonvulsant activity of CPPene and NBQX in DBA/2 mice. *J. Pharm. Pharmacol.*, *46*, 1017-1022
2. De Sarro G.B., Ammendola D., **Nava F.**, De Sarro A., 1995. Effects of some excitatory amino acid antagonists on imipenem induced seizures in DBA/2 mice. *Brain Res.*, *671*, 131-140
3. Gareri P., Mattace R., **Nava F.**, De Sarro G.B., 1995. Role of calcium in brain aging. *Gen. Pharmacol.*, *26*, 1651-1657
4. De Sarro G.B., **Nava F.**, Aguglia U., De Sarro A., 1996. Lamotrigine potentiates the antiseizures activity of some anticonvulsant in DBA/2 mice. *Neuropharmacology*, *35*, 153-158
5. **Nava F.**, Calapai G., De Sarro A., Caputi A.P., 1996. Interleukin-1 receptor antagonist does not reverse lipopolysaccharide induced inhibition of water intake in rats. *Eur. J. Pharmacol.*, *309*, 223-227
6. Cuzzocrea S., Zingarelli B., Calapai G., **Nava F.**, Caputi A.P., 1997. Zymosan-activated plasma induced paw oedema by nitric oxide and prostaglandin production. *Life Sci.*, *60*, 215-220
7. Calapai G., Parente L., **Nava F.**, Facciola G., Marciano M.C., Caputi A.P., 1997. Interleukin-1 inhibits drinking behaviour through prostaglandins, but not by nitric oxide. *Life Sci.*, *60*, 457-464
8. De Sarro G.B., **Nava F.**, Calapai G., De Sarro A., 1997. Effects of some excitatory amino acid antagonists and drugs enhancing gamma-aminobutyric acid-stimulatory transmission on pefloxacin-induced seizures in DBA/2 mice. *Antimicrob. Agents Chemother.*, *41*, 427-434
9. **Nava F.**, Calapai G., Facciola G., Cuzzocrea S., Marciano M.C., De Sarro A., Caputi A.P., 1997. Effects of interleukin-10 on water intake, locomotory activity, and rectal temperature in rats treated with endotoxin. *Int. J. Immunopharmacol.*, *19*, 31-38
10. De Sarro A., Grasso S., Zappalà M., **Nava F.**, De Sarro G.B., 1997. Convulsant effects of some xanthine derivatives in genetically epilepsy-prone rats. *Nauyn-Schmiedeberg's Arch. Pharmacol.*, *356*,

48-55

11. **Nava F.**, Calapai G., Facciola G., Cuzzocrea S., Giuliani G., De Sarro A., Caputi A.P., 1997. Melatonin effects on thirst and fever induced by lipopolysaccharide in rat. *Eur. J. Pharmacol.*, 331, 267-274
12. Cuzzocrea S., Zingarelli B., Saubetin L., Rizzo A., Crisafulli C., Campo G.M., Costantino G., Calapai G., **Nava F.**, Di Rosa M., Caputi A.P., 1997. Multiple organ failure following zymosan-induced peritonitis is mediated by nitric oxide. *Shock*, 8, 268-275
13. Carta G., **Nava F.**, Gessa G.L., 1998. Inhibition of hippocampal acetylcholine release after acute and repeated delta9-tetrahydrocannabinol in rats. *Brain Res.*, 809, 1-4
14. **Nava F.**, Caputi A.P., 1999. Central effects of disodium cromoglycate in rats. *Eur. J. Pharmacol.*, 307, 351-358
15. Bonina F.P., Arenare L., Palagiano F., Saija A., **Nava F.**, Trombetta D., de Caprariis P., 1999. Synthesis, stability, and pharmacological evaluation of nipecotic acid prodrugs. *J. Pharm. Sci.*, 88, 561-567
16. Carta G., Gessa G.L., **Nava F.**, 2000. Dopamine D² receptor antagonist prevent Delta⁹-tetrahydrocannabinol-induced antinociception in rats. *Eur. J. Pharmacol.*, 384, 153-156
17. **Nava F.**, Carta G., Gessa G.L., 2000. Permissive role of dopamine D(2) receptors in the hypothermia induced by delta(9)-tetrahydrocannabinol in rats. *Pharmacol. Biochem. Behav.*, 66, 183-187
18. **Nava F.**, Carta G., Haynes L.W., 2000. Lipopolysaccharide increases arginine-vasopressin release from rat suprachiasmatic nucleus slice cultures. *Neurosci. Lett.*, 288, 228-230
19. **Nava F.**, Carta G., Battasi A.M., Gessa, G.L., 2000. D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration. *Br. J. Pharmacol.*, 130, 1201-1210
20. **Nava F.**, Carta G., 2000. Repeated lipopolysaccharide administration produces tolerance to anorexia and fever but not to inhibition of thirst in rat. *Int. J. Immunopharmacol.*, 22, 943-953
21. Giuffrida A., Rodriguez de Fonseca F., **Nava F.**, Loubet-Lescoulié P., Piomelli D., 2000. Elevated circulating levels of anandamide after administration of the transport inhibitor, AM 404. *Eur. J. Pharmacol.*, 408, 161-168
22. **Nava F.**, 2001. Cannabinoids: do not use them without a medical prescription! *Trends in Pharmacological Sciences*, 22, 13-14
23. **Nava F.**, Carta G., 2001. Melatonin reduces anxiety induced by lipopolysaccharide in the rat. *Neurosci. Lett.*, 307, 57-60
24. **Nava F.**, Carta G., Colombo G., Gessa G.L., 2001. Effects of chronic delta-9-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze. *Neuropharmacology*, 41, 209-212
25. **Nava F.**, Carta G., Bortolato M., Gessa G.L., 2001. Gamma-hydroxybutyric acid and baclofen decrease extracellular acetylcholine levels in the hippocampus via GABA^B receptors. *Eur. J. Pharmacol.*, 430, 261-263
26. Rodriguez de Fonseca, Navarro M., Gomez R., Scuredo L., **Nava F.**, Fu J., Murillo-Rodriguez E., Giuffrida A., LoVerme J., Gaetani S., Kathuria S., Gall C., Piomelli D., 2001. An anorexic lipid mediator regulated by feeding. *Nature*, 418, 208-212
27. Gomez R., Navarro M., Ferrer B., Trigo J.M., Bilbao A., Del Arco I., Cippitelli A., **Nava F.**, Piomelli D., Rodriguez de Fonseca F., 2002. A peripheral mechanism for CB¹ cannabinoid receptor-dependent modulation of feeding. *J. Neurosci.*, 22, 9612-9617
28. **Nava F.**, Caldiroli E., Premi S., Lucchini A., 2006. Relationship between plasma cortisol levels, withdrawal symptoms and craving in abstinent and treated heroin addicts. *J. Addictive Disease*, 25, 9-16
29. **Nava F.**, Premi S., Manzato E., Lucchini A., 2006. Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumptions. *J. Psychoactive Drugs*, 38, 211-217
30. **Nava F.**, Premi S., Manzato E., Campagnola W., Lucchini A., Gessa G.L., 2007. Gamma-hydroxybutyrate reduced hypercortisolism in severe abstinent alcoholics: an open randomised study. *Am. J. Drug Alcohol Abuse*, 33, 379-392
31. **Nava F.**, Manzato E., Lucchini A., 2007. Chronic cannabis use does not affect the normalization of hypothalamic-pituitary-adrenal (HPA) axis induced by methadone in heroin addicts. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry*, 31, 1089-1094
32. **Nava F.**, 2008. Reply to the letter "Are the effects of gamma-hydroxybutyrate (GHB) treatment partly physiological in alcohol dependence?". *Am. J. Drug Alcohol Abuse*, 34, 1-2
33. **Nava F.**, Manzato E., Leonardi C., Lucchini A., 2008. Opioid maintenance therapy suppresses alcohol intake in heroin addicts with alcohol dependence: preliminary results of an open randomised study. *Prog. Neuro-Psychopharmacol. Biol. Psychiatry*, 32, 1867-1872
34. **Nava F.**, Vendramin A., Cibin M., Lucchini A. 2010. New frontiers in alcoholism and addiction treatment. *Recent Patents on CNS Drug Discovery*, 5, 81-93
35. Stofollini T., D'Egidio P.F., Aceti A., Filippini P., Puoti M., Leonardi C., Almasio P.L., DAVIS Drug Addicted, HCV Prevalence in Italy an Epidemiological Observational Cross-Sectional, Multicenter Study Participating Centers, 2012. Hepatitis C virus infection among drug addicts in Italy. *J. Med.*

Viol., 84: 1608-1612

36. Fischer G., **Nava F.**, Stover H. 2012. Outcomes of opioid dependence treatment across Europe: identifying opportunities for improvement, *Heroin Addict Relat Clin Probl*, 14(4), 39-50
37. Monarca R., Madeddu G., Ranieri R., Carbonara S., Leo G, Sardo M., Choroma F., Casari S., Marri D., Muredda A.A., **Nava F.**, Babudieri S. 2015. HIV treatment and care among Italian inmates: a one-month point survey. *BMC Infection Diseases*, *BMC Infection Diseases*, 15, 1301-1305
38. Michel L., Brentari C., Lions C., Van Malderen S., Schiltz J., Vanderplasschen W., Holm K., Kolind T., **Nava F.**, Weltzien N., Moser A., Jauffet-Roustide J., Maguet O., Carrieri M.P., Stover H. 2015. Insufficient access to harm reduction measures in prisoners in 5 countries (PRIDE Europe) a shared European public health concern, *BMC Public Health*, 15 (1), 1093
39. Contalbrigo L., De Sanctis M., Toson M., Montanaro M., Farina L., Costa A., **Nava F.A.** 2017. The efficacy of dog assisted therapy in detained drug users: a pilot study in an Italian attenuated custody institute, *Int. J. Environ. Res. Public Health*, 14(7). Pii E683. Doi: 10.3390/ijerph14070683
40. **Nava F.A.**, Alberti A., Andreoni M., Babudieri S., Barbarini G., d'Egidio P.F., Leonardi C., Lucchini A. 2018. For a program of eradication of hepatitis C in the population at risk (drug users and convicts). *Acta Biomed.*, 89 (Suppl. 10), 33-41.
41. **Nava F.A.** 2018. HCV infection and drug use in Italian detainees: results of validation of EQDP (European Questionnaire on Drug Use in Prison). *Acta Biomed.*, 89 (Suppl. 10), 54-67.
42. Lucchini F., Bastiani L., Benedetti E., Fea M., **Nava F.**, Molinaro S., 2018. What predicts outcome of an internet-delivery therapy? The role of socio-economic status of gambling behaviour. *Mission – Italian Quarterly Journal of Addiction*, 50, 7-14.
43. Stover H., Meroueh F, Marco A., Keppler K., Saiz de la Hoya P., Littlewood R., Wright N., **Nava F.**, Alam F., Walcher S., Somaini L., 2019. Offering HCV treatment to prisoners is an important opportunity: key principles based on policy and practice assessment in Europe. *BMC Public Health*, 19: 30.
44. Cozzolino E., D'Egidio P.F., De Facci R., Leonardi C., **Nava F.**, Stella L., Maremmani I., 2019. Improving response capacities in opioid overdose management. *Heroin Addiction & Related Clinical Problems*, 21: 5-14.
45. Molinaro S., Resce G., Albert A., Andreoni M., D'Egidio P.F., Leonardi C., **Nava F.A.**, Pasqualetti P., Villa S., 2019. Barriers to effective management of hepatitis C virus in people who inject drugs: evidence from outpatient clinics. *Drug and Alcohol Rev.* 38 (6): 644-655
46. Testoni I., Branciforti G., Zamperini A., Zuliani L., **Nava F.A.**, 2019. Prisoners' ambivalent sexism and domestic violence: a narrative study. *Int. J. Prison Health*, 15: 332-348.
47. Kakko J., Alho H., Baldacchini A.M., Molina R., **Nava F.A.**, Shaya G., 2019. Craving in opioid use disorder: from neurobiology to clinical practice. *Front. Psychiatry*, 10: 592, doi: 10.3389/fpsy.2019.00592
48. Addolorato G., Lesch O.M., Maremmani I., Walte H., **Nava F.**, Raffailac Q., Caputo F., 2019. Post-marketing and clinical safety experience with sodium oxybate for the treatment of alcohol withdrawal syndrome and maintenance of abstinence in alcohol-dependent subjects. *Expert. Opin. Drug Saf.*, 30: 1-8.
49. Testoni I., Bonelli B., Biancalani G., Zuliani L., **Nava F.A.**, 2020. Psychodrama in attenuated custody prison-based treatment of substance dependence: the promotion of changes in wellbeing, spontaneity, perceived self-efficacy, and alexithymia. *The Arts in Psychotherapy*, 68: 101650.

Books

1. **Nava F.**, Caldiroli E., Marino V., 2002. La dipendenza da oppiacei: l'esperienza dell'uso della buprenorfina del Dipartimento delle Dipendenze della ASL della Provincia di Varese, *Editeam Editore, Bologna*
2. **Nava F.**, 2004. Manuale di Neurobiologia e Clinica delle Dipendenze, *Franco Angeli Editore, Milano*
3. Ferdico M., Gerra G., Leonardi C., **Nava F.**, Sbrana A. (Editors), 2005. Buprenorfina e kappa antagonismo, *One Way s.r.l., Milano*
4. Barbaro G., Nava F., Barbarini G., Lucchini A. (Editors), 2007. Management of Associated Medical Conditions in Cocaine and Heroin Addicts, *Nova Publishers Inc., New York*
5. Lucchini A., **Nava F.**, Manzato E., 2008 (Editors). Buone pratiche e procedure terapeutiche nella gestione del paziente alcolista, *Franco Angeli Editore, Milano*
6. Forcella M.C., Bergamo L.C., **Nava F.**, Onori F., Bergamo A., 2009 (Editors). Dipendenze. Insegnanti e genitori che fare? *CIC Edizioni Internazionali, Roma*
7. Lucchini A., Leonardi C., **Nava F.**, Sanfilippo B., 2009 (Editors). ItaliaAlcol. Studi e Ricerche in alcoologia, *Franco Angeli Editore, Milano*
8. Lucchini A., D'Egidio P.F., **Nava F.**, 2013 (Editors). Attualità ed innovazioni nel trattamento con metadone. Percorsi diagnostico-terapeutici nei Servizi per le Dipendenze Italiani. *Franco Angeli Editore, Milano*
9. Raffaelli W., **Nava F.**, 2017 (Editors). Il dolore in area penitenziaria. Quadri clinici prevalenti e principi di diagnosi e terapia. *Fondazione ISAL, Rimini*
10. **Nava F.**, Manzato E., 2018 (Editors). Il craving dell'alcolista: neurobiologia, clinica e trattamento,

Ce.R.Co Edizioni, 7, Milano

11. Varango C., Riglietta M., Corti M., Sanfilippo B., **Nava F.**, (2019) (Editors). *Riparliamo di alcol. Ce.R.Co Edizioni, 9, Milano*

Book chapters

1. **Nava F.**, Caldiroli E., Fonzi S., Tosetto C., Marino V., 2002. La buprenorfina nel trattamento della dipendenza da oppiacei in soggetti fumatori cronici di cannabis. In: *L'uso della buprenorfina nel trattamento della tossicodipendenza*, Franco Angeli Editore, 273-279
2. Tosetto C., **Nava F.**, Caldiroli E., 2003. Sostanze a "effetto speciale". In: *Dipendenze i legami pericolosi*, McGraw Hill, Milano, 29-74
3. Caputi A.P., Calapai G., **Nava F.**, 2004. I metalli. In: *Tossicologia Medica*, UTET, 134-147
4. **Nava F.**, 2005. La farmacologia della buprenorfina. In: *Bruprenorfina e kappa antagonismo*, One Way Publishing, Milano, 9-21
5. **Nava F.**, 2006. La neurobiologia della nicotina: corrispettivo clinico e razionale per il trattamento farmacologico della dipendenza da tabacco. In: *Il Trattamento del Tabagismo. Linee guida per il medico di famiglia*, A cura di E. Massimo Diana, Regione Sardegna Editore, 45-64
6. **Nava F.**, 2006. Trattamenti neurofarmacologici. In: *In dipendenze: Trattamenti per le Tossicodipendenze Vol. 2*, Franco Angeli Editore, Milano
7. **Nava F.**, 2007. Le radici neurobiologiche nell'approccio cognitivo-comportamentale del cocainismo. In: *Cocaina: da piacere a patologia. L'esperienza di un trattamento non farmacologico ambulatoriale*, Franco Angeli Editore, Milano, 27-33
8. **Nava F.**, Lucchini A., 2007. Heroin and cocaine: neurobiology and clinical aspects. In: *Barbaro G., Nava F., Barbarini G., Lucchini A. (Editors), 2007. Management of Associated Medical Conditions in Cocaine and Heroin Addicts*, Nova Publishers Inc., New York, 1-22
9. **Nava F.**, 2007. Detoxification programs and other therapeutic strategies. In: *Barbaro G., Nava F., Barbarini G., Lucchini A. (Editors), 2007. Management of Associated Medical Conditions in Cocaine and Heroin Addicts*, Nova Publishers Inc., New York, 35-62
10. Lucchini A., **Nava F.**, 2007. Clinical aspects of the medical conditions associated with drug abuse. In: *Barbaro G., Nava F., Barbarini G., Lucchini A. (Editors), 2007. Management of Associated Medical Conditions in Cocaine and Heroin Addicts*, Nova Publishers Inc., New York, 63-79
11. **Nava F.**, Manzato E., 2008. Biochemical measures of alcohol consumption. In: *Research on the neurobiology of alcohol use disorders*, Sher L. Editor, Nova Publishers Inc., New York, 33-46
12. **Nava F.**, Gerra G., Lucchini A., 2008. The effects of steroids on the brains: pathophysiological consequences and therapeutic use. In: *Adverse effects of steroids*, Nova Publishers Inc., New York, 109-115
13. **Nava F.**, Gerra G., Lucchini A., 2008. New challenges in the addiction research: the neurosecretory system as therapeutic target. In: *New Research on Neurosecretory System*, Nova Publishers Inc., New York, 117-125
14. **Nava F.**, Passudetti C., 2008. Le radici neurobiologiche dell'intervento psicoterapeutico nei consumatori di sostanze. In: *Interventi innovativi per le Dipendenze Patologiche*, a cura di Angelino R., Gilardini A., Edizioni Publiedit, 99-112
15. **Nava F.**, 2009. Eroina, Cocaina, Ecstasy, Amfetamine e Metamfetamine, Smart Drugs, Allucinogeni, Alcol. In: *Dipendenze. Insegnanti e genitori che fare? A cura di Forcella M.C., Bergamo L.C., Nava F., Onori F., Bergamo A., CIC Edizioni Internazionali, Roma, 85-118*
16. **Nava F.**, Manzato E., Borrono G., Danielli D., De Re A., Fertoni G., Gasparini G.L., Giacomini M.A., Molinaroli E., Richini M., Torriani M., Thoux M., 2009. L'uso del GHB in pazienti alcolodipendenti in trattamento: uno studio retrospettivo nei Servizi di Alcolologia del Nord Italia (The GUM – GHB USE and MISUSE – STUDY). In: *Lucchini A., Leonardi C., Nava F., Sanfilippo B. 2009 (Editors). ItaliaAlcol. Studi e Ricerche in alcolologia*, Franco Angeli Editore, Milano, 70-115
17. Leonardi C., Somaini L., Cortese E., Fagetti R., Lucchini A., **Nava F.**, Pascucci A., Rocchi L., Ventre G., Gerra G., 2009. Dipendenza da alcol e disturbo da deficit d'attenzione con iperattività. Studio sul ruolo terapeutico del GHB nel controllo dell'astinenza e del craving in alcolisti ADHD positivi in trattamento. In: *Lucchini A., Leonardi C., Nava F., Sanfilippo B. 2009 (Editors). ItaliaAlcol. Studi e Ricerche in alcolologia*, Franco Angeli Editore, Milano, 116-139
18. **Nava F.**, 2009. L'alleanza terapeutica come strumento di cura: radici neurobiologiche e implicazioni cliniche. In: *Fea M., 2009. Manuale critico sull'affido dei farmaci oppiacei*, Franco Angeli Editore, Milano, 32-44
19. **Nava F.**, 2010. La doppia diagnosi e l'integrazione dei trattamenti fra criticità organizzative e gestionali: l'esperienza della Regione Veneto. In *Lucchini A., Strepparola G. (Editors). Modelli di interventi in alcolologia. L'esperienza e le indicazioni operative condivise degli operatori pubblici e privati in Lombardia*, Franco Angeli Editore, Milano, 97-104.
20. Cibin M., **Nava F.**, 2011. Psicobiologia del craving. In: *Hinnenthal I., Cibin M. Il trattamento*

- residenziale breve delle dipendenze da alcol e cocaina. SEEd Torino, 65-79
21. Nava F., 2011. Droghe e comportamenti di Addiction. In: Lucchini A., Cicerone P.E. Oltre l'Eccesso, Franco Angeli Editore, Milano, 125-131
 22. **Nava F.**, 2011. Alcolismo e sessualità: aspetti neurobiologici e comportamentali, In: Avenia F., Pistuddi A. Sessualità e dipendenze: dal desiderio alla violenza, Franco Angeli Editore, Milano, 117-125
 23. Cibir M., Hinnenthal I., **Nava F.**, Ferdico M., 2011. Focus sui disturbi di personalità, schizofrenia, paranoia e isteria. In: Gasbarrini G. Trattato di Medicina Interna Vol. 2, Verducci Editore, 2377-2387
 24. **Nava F.**, Leonardi C., 2012. Poliabusatori. In: Serpelloni G., Randazzo L., Marino V. Zero Coca: Linee Operative per la Diagnosi, il Trattamento e la Riabilitazione delle Persone Dipendenti da Cocaina, Dipartimento Politiche Antidroga, Roma, 214-220
 25. Cibir M., **Nava F.**, Hinnenthal I., 2013. Le basi biologiche dell'addiction. In: Cibir M., Lucchini A., Rossi S. La Gestione delle Dipendenze da Alcol in Medicina Generale, Pacini Editore Medicina, 9-12
 26. **Nava F.**, 2013. Benzodiazepine e poliabuso. In: Benzodiazepine: uso, abuso e dipendenza. Dall'epidemiologia al trattamento. Edizioni Clad-Onlus, Verona, 213-228
 27. **Nava F.**, 2013. Detenuti in sciopero della fame. In: Prigioni d'Italia la Difesa degli Ultimi. A cura dell'Osservatorio Carcere dell'Unione delle Camere Penali Italiane, Parini Editore.
 28. **Nava F.**, 2013. Benzodiazepine e poliabuso. In: Benzodiazepine: uso, abuso e dipendenza. Dall'epidemiologia al trattamento. Edizioni Clad-Onlus, Verona, 253-262
 29. **Nava F.**, 2014. Malattia. In: Atlante delle dipendenze. Edizioni Gruppo Abele, Torino, 39-43
 30. **Nava F.**, Pozzetti G., Scarabello G. 2015. Il metadone: una voce fuori dal coro. In: Analgesici oppioidi. Uso, abuso e addiction. Diagnosi e trattamento di un fenomeno sommerso. Edizioni Clad-Onlus, Verona, 187-195
 31. **Nava F.**, 2016. Detoxification. The Sage Encyclopedia of abnormal and clinical psychology. Ed. Amy E. Wenzel
 32. **Nava F.**, Raffaelli W., 2017. Proposta di un PDTA per la gestione del dolore nell'area della sanità penitenziaria. In: Il dolore in area penitenziaria. Quadri clinici prevalenti e principi di diagnosi e terapia, Fondazione ISAL, Rimini, 113-118
 33. Lageder D., Morgillo G., Zuliani L., **Nava F.**, 2017. I principali orientamenti terapeutici e suggerimenti operativi per il trattamento del dolore cronico non oncologico. In: Il dolore in area penitenziaria. Quadri clinici prevalenti e principi di diagnosi e terapia, Fondazione ISAL, Rimini, 119-128
 34. **Nava F.**, 2018. La Neurobiologia del craving: le evidenze della ricerca sperimentale nella pratica clinica. In: In Sostanza. Manuale sulle Dipendenze Patologiche, Edizioni CLAD Onlus, Verona, 91-105
 35. Lugoboni F., Fantozzi F., **Nava F.**, 2018. Curare l'abuso degli analgesici oppioidi. In: In Sostanza. Manuale sulle Dipendenze Patologiche, Edizioni CLAD Onlus, Verona, 308-313
 36. **Nava F.**, Manzato E., 2018. Introduzione. In: Il craving dell'alcolista. Neurobiologia, clinica e trattamento. Ce.R.Co Edizioni, 7 Milano, 7-11.
 37. **Nava F.**, Manzato E., 2018. Il craving dell'alcolista: aspetti neurobiologici, cognitivi e neuropsicologici. In: Il craving dell'alcolista. Neurobiologia, clinica e trattamento. Ce.R.Co Edizioni, 7, Milano, 13-32.
 38. Manzato E., **Nava F.**, De Rosa M.G.L., Rosa S., Manzato G., Biasin C., Cifelli G., Cibir M., Lucchini A., 2018. Gli aspetti clinici e le tipologie del craving: In: Il craving dell'alcolista. Neurobiologia, clinica e trattamento. Ce.R.Co Edizioni, 7, Milano, 41-95.
 39. **Nava F.**, Manzato E., 2018. Il trattamento farmacologico del craving alcolico. In: Il craving dell'alcolista. Neurobiologia, clinica e trattamento. Ce.R.Co Edizioni, 7, Milano, 109-140.
 40. **Nava F.**, Manzato E., 2018. Conclusioni. In: Il craving dell'alcolista. Neurobiologia, clinica e trattamento. Ce.R.Co Edizioni, 7, Milano, 141-142.
 41. **Nava F.**, 2019. Alcolologia e alcolodipendenza oggi. In: Varango C., Riglietta M., Corti M., Sanfilippo B., Nava F., 2019 (Editors). Riparliamo di alcol. Ce.R.Co Edizioni, 9, Milano

Articles in Italian journa

1. **Nava F.**, 2003. Farmaci e craving, *Medicina delle Tossicodipendenze (It. J. Addict.)*, 40, 31-38
2. **Nava F.**, Rossi D., 2004. Il rischio suicidario nell'abuso di sostanze: revisione della letteratura, *Medicina delle Tossicodipendenze (It. J. Addict.)*, 42, 7-15
3. **Nava F.**, 2004. Tra scienza e pregiudizi, *Medici Oggi, Anno VIII – n. 8*: 239
4. **Nava F.**, 2004. La neurobiologia delle sostanze d'abuso, *Medici Oggi, Anno VIII – n. 8*, 240-242
5. **Nava F.**, 2004. Il trattamento del dolore nel tossicodipendente e nell'alcolista, *Medicina delle Tossicodipendenze (It. J. Addict.)*, 45, 27-37
6. **Nava F.**, 2006. L'uso del gamma-idrossibutirrato di sodio (GHB) negli eroinomani alcolisti: aspetti critici e possibili modalità d'uso. *Aggiornamenti in Psichiatria*, 8, 1-10
7. Manzato E., Biasin C., **Nava F.**, 2006. La diagnosi nei disturbi da uso di sostanze psicoattive e nella

comorbidità psichiatrica associata. *Mission*, 17, 21-30

8. Manzato E., **Nava F.**, Biasin C., Zimbello F., Faccini M., Cifelli G., Zanoni C., 2006. Gli esami di laboratorio e le indagini strumentali nell'assessment dei disturbi correlati a sostanze psicoattive in soggetti con comorbidità psichiatrica, *Mission*, 20, 19-34

9. D'Egidio P., Fea M., Leonardi C., **Nava F.**, Salvadori S., Il valore dell'esperienza e le evidenze scientifiche. Conferenza di consenso per i percorsi degli interventi di prevenzione e di cura, *FeDerSerD Informa*, n. 7, 1-12

10. Leonardi C., **Nava F.**, 2007. L'uso del Gamma-Idrossibutirrato (GHB) e della Buprenorfina nel paziente politossicodipendente, *Mission*, 23, 2-7

11. **Nava F.**, 2008. Una guida per chi guida, *Medicom Editore, Milano*

12. **Nava F.**, 2008. Realtà e prospettive farmacologiche nell'affido di terapie specifiche per il trattamento della tossicodipendenza da oppiacei, *FeDerSerD Informa*, n. 9, 2-13

13. **Nava F.** 2009. Le Ragioni della nascita della Newsletter "Clinica dell'Alcolismo", *Newsletter Clinica dell'Alcolismo*, n. 1, 27-30

14. Bignamini E., Carboni G., D'Egidio P.F., Gardini A., Gonzalez-Saiz F., Leonardi C., Lucchini A., **Nava F.**, Pacini M., Sartori M.F., 2008. Validazione culturale e linguistica del questionario ODAS utilizzato per definire l'adeguatezza del dosaggio giornaliero di metadone nel contesto di un programma di mantenimento per il trattamento della dipendenza da oppiacei. *Mission*, 26, 5-18

15. Cibir M., Addolorato G., Hinnenthal I., Manzato E., Mosti A., **Nava F.**, Zavan V., 2008. Il craving nella dipendenza da alcol: fisiopatologia, diagnosi e trattamento. *Newsletter Clinica dell'Alcolismo*, n. 2, 31-49

16. **Nava F.**, 2008. Update della ricerca clinica in Italia nell'alcolismo e nelle tossicodipendenze. *Mission*, 26, 74

17. Leonardi C., Assi C., Bandini C., Broccoli N., D'Angelo C., D'Egidio P.F., Dell'Eva I., Della Torre N., Fredda E., Gottardi M., Laurenzi P., Lodolini M., Calligara M., Lodi F., Lotto A., Lovaste R., Mozzo M., **Nava F.**, Pieri C., Rocchi L., Ventre G., Svaizer F., Lucchini A., 2008. Studio multicentrico nazionale per la valutazione della potenza analitica di un metodo di dosaggio in matrice cheratinica. *Mission*, 28, 19-22

18. Manzato E., **Nava F.**, Cifelli G., Biasin C., Galvanin F. 2010. L'assessment di I° livello per la valutazione alcolologica nella pratica clinica dei Servizi. *Newsletter Clinica dell'Alcolismo*, n. 6, 27-52

19. Hinnenthal H., **Nava F.**, Ferdico M., Cibir M., 2010, *Newletter Clinica dell'Alcolismo*, n. 7, 29-39

20. **Nava F.**, 2010, La ricerca clinica applicata nella clinica delle dipendenze: fra innovazione e necessità. *Mission*, 32, 1-3

21. Lucchini A., D'Egidio P.F., Bignamini E., Leonardi C., **Nava F.**, 2010. La scala ODAS in un campione di eroinomani in trattamento con buprenorfina nei Ser.T. italiani: uno studio di validazione e affidabilità. *Mission*, 32, 17-26

22. **Nava F.**, Lucchini A., Leonardi C., 2010. L'efficacia dell'acamprosato nel trattamento dell'alcolismo, le evidenze del Cochrane collaboration group. *Mission*, 32, 27-32

23. **Nava F.**, 2011. Il matching trattamentale nella clinica delle dipendenze: un'esigenza di appropriatezza nei fenomeni di uso e polibuso. *Italian Journal of Addiction Research*, 2, 3-10

24. **Nava F.**, D'Egidio P., Cecchini I., Fregosi S., Lucchini A., 2011. Il misuse e la diversione nella terapia agonista nei SerT italiani: dati dello studio DeMoS. *Italian Journal of Addiction Research*, 1 (special issue), 1, 5-14

25. Manzato E., **Nava F.**, Biasin C., Cifelli G., Manzato G., Rosa S., D'Agostini G., 2012. Il trattamento dei disturbi d'ansia nell'alcolismo. *Newsletter Clinica dell'Alcolismo*, n. 12, 41-53

26. Manzato E., **Nava F.**, Biasin C., Cifelli G., Manzato G., Rosa S., D'Agostini G., 2013. Il trattamento dei disturbi depressivi nell'alcolismo. *Newsletter Clinica dell'Alcolismo*, n. 13, 29-41

27. Manzato E., **Nava F.**, Biasin C., Cifelli G., Manzato G., Rosa S., D'Agostini G., 2013. Aspetti generali della terapia psicofarmacologica nel trattamento dell'alcolismo. *Mission*, n. 38, 60-70

28. Manzato E., **Nava F.**, Biasin C., Cifelli C., Manzato G., Rosa S., D'Agostini G., 2013. Il trattamento dei disturbi psicotici nell'alcolismo. *Newsletter Clinica dell'Alcolismo*, n. 15, 30-45

29. Manzato E., **Nava F.**, Biasin C., Cifelli G., Manzato G., Rosa S., D'Agostini G., 2013. Il trattamento dei disturbi bipolari nell'alcolismo. *Newsletter Clinica dell'Alcolismo*, n. 16, 44-58

30. Manzato E., Lugoboni F., Biasin C., Rosa S., Cifelli G., Manzato G., **Nava F.**, 2014. Le benzodiazepine ed i disturbi d'ansia: utilizzo clinico corretto, abuso, dipendenza e strategie di disassuefazione. *Mission*, 42, 15-28

31. Canton S., Crescini D., De Facci R., Lucchini A., Pimpini M., **Nava F.**, 2015. La continuità assistenziale in alcologia: realtà, criticità e prospettive dell'esperienza di Addiction Center. *Newsletter Clinica dell'Alcolismo*, n. 19, 49-52

32. Manzato E., Lugoboni F., Biasin C., Rosa S., Cifelli G., Manzato G., **Nava F.**, 2015. Le strategie di disassuefazione da benzodiazepine: metodologia di intervento, terapie farmacologiche, interventi psicologici e outcome del trattamento. Parte II. *Mission*, 43, 64-83

33. Manzato E., **Nava F.**, Manzato G., Rosa S., 2015. La terapia farmacologica dell'alcolismo: i farmaci anti-alcol vecchi e nuovi e l'integrazione con gli interventi psicologici nella pratica clinica. Parte I. *Newsletter Clinica dell'Alcolismo*, n. 20, 45-60

34. D'Egidio F., **Nava F.**, Faillace G., Riglietta M., Lucchini A., 2016. Terapia del dolore severo e

- dipendenza in Italia: il ruolo di FeDerSerD, *Mission*, 45, 13-16.
35. Manzato E., **Nava F.**, Manzato G., Rosa S., Caputo F., 2016. La terapia farmacologica dell'alcolismo: il disulfiram ed il naltrexone: i primi due farmaci anti-alcol approvati dagli organismi regolatori per la pratica clinica. Parte II. *Newsletter Clinica dell'Alcolismo*, n. 21, 19-48
36. Manzato E., **Nava F.**, Manzato G., Rosa S., Caputo F., 2016. La terapia farmacologica dell'alcolismo: il sodio oxibato (acido gamma-idrossi butirrico – GHB) farmaco antialcol approvato dall'organismo regolatorio italiano per la pratica clinica. Parte III. *Newsletter Clinica dell'Alcolismo*, n. 22, 17-48
37. Manzato E., **Nava F.**, Borroni G., Bosticco E., Bravin S., Fertonani Affini G., Gasparini G., Richini M., Thoux M., Torriani M., Lucchini A., 2016. L'efficacia, la sicurezza e la maneggevolezza del sodio oxibato: i risultati dello studio GUM (GHB – Use and Misuse), *Newsletter Clinica dell'Alcolismo*, n. 22, 49-55
38. **Nava F.**, 2017. La modernità della clinica delle dipendenze: fra mutazioni e cambiamenti scientifici per un diverso approccio clinico ed organizzativo dei servizi. *Mission*, 47, 1-2
39. **Nava F.**, 2017. La terapia farmacologica dell'alcolismo: quali i limiti e le prospettive per l'implementazione dei trattamenti. *Newsletter Clinica dell'Alcolismo*, n. 23, 15-20
40. Manzato E., **Nava F.**, Manzato G., Rosa S., Caputo F., 2017. La terapia farmacologica dell'alcolismo: l'acamprosato e il nalmeffene i due farmaci anti-alcol approvati dagli organismi regolatori per la pratica clinica. Parte IV. *Newsletter Clinica dell'Alcolismo*, n. 23, 26-58
41. Manzato E., **Nava F.**, Manzato G., Rosa S., Caputo F., 2017. La terapia farmacologica dell'alcolismo. I farmaci anti-alcol non ancora autorizzati dagli organismi regolatori ma utilizzati nella pratica clinica o in fase di sperimentazione. I farmaci che modulano il sistema del glutammato ed il gabapentin. Parte V. *Newsletter Clinica dell'Alcolismo*, n. 24, 19-46
42. Lucchini F., Fea M., **Nava F.**, 2017. Evidenze preliminari della piattaforma terapeutica online giocaresponsabile. Condizioni socio-economiche e comportamenti di gioco. *Mission*, 48, 66-70.
43. **Nava F.A.**, 2018. Verso un algoritmo per il trattamento olistico del consumatore di sostanze con epatite C. Inside PWID, Quaderno di Read File, suppl. 1, n. 4, 29-30.
44. **Nava F.A.**, Alberti A., Andreoni M., Babudieri S., Barbarini G., D'Egidio P.F., Leonardi C., Lucchini A., 2018. Gli algoritmi. Inside PWID, Quaderno di Read File, suppl. 1, n. 4, 31-34.
45. Lageder D, Morgillo G., Zuliani L., Padovan G.B., Lorenzon J., **Nava F.**, 2018. Orientare l'organizzazione dei Servizi verso un modello efficace e sicuro di trattamento del dolore con farmaci oppiacei: l'esperienza della Casa di Reclusione di Padova. *Mission*, 49, 10-15.
46. **Nava F.A.**, Alberti A., Andreoni M., Babudieri S., Barbarini G., D'Egidio P.F., Leonardi C., Lucchini A., 2018. Position paper per un programma di eliminazione dell'Epatite C nella popolazione a rischio dei consumatori di sostanze e dei detenuti. *Mission*, 49, 56-61.
47. **Nava F.**, Zaccarelli M., 2018. Superare le barriere per la presa in carico nei PWID. In: Sfide e opportunità per l'eradicazione di HCV nei co-infetti da HCV. Quaderno di ReAd files. Suppl. n. 1 Rivista del 01.03.18, Anno 19, 28-31.
48. **Nava F.**, Zaccarelli M., 2018. Focus sui consumatori di sostanze. In: Sfide e opportunità per l'eradicazione di HCV nei co-infetti da HCV. Quaderno di ReAd files. Suppl. n. 1 Rivista del 01.03.18, Anno 19, 31.
49. **Nava F.A.**, Padovan G.B., 2018. Il management della terapia con buprenorfina/naloxone nei consumatori di sostanze in carcere: efficacia e sicurezza. *AboutOpen*, 4(1): 13-28.
50. **Nava F.A.**, 2018. Come intercettare precocemente la nuova utenza. Nonno libro Bianco sulle Droghe. I dossier di Fuoriluogo.it, 29-30.
51. **Nava F.A.**, 2018. Modello integrato di presa in carico del PWID con HCV: ritorno di salute e costi evitabili per il sistema sanitario. *ReAd files*, 3: 35-38.
- Alberti A., Andreoni M., D'Egidio P.F., Leonardi C., Molinaro S., **Nava F.A.**, Pasqualetti F., Resce G., Villa S., 2018. Ostacoli a una gestione efficace del virus dell'epatite C nelle persone che fanno uso di droghe iniettabili: evidenze da uno studio Delphi modificato in una ampia coorte di operatori dei Ser.D. *FeDerSerD Informa*, 32, 12-14.
53. **Nava F.A.**, 2019. I Ser.D. come presidi sul territorio: il ruolo dei Servizi nell'eliminazione di HCV. In: *SimplyC Popolazioni speciali: difficilmente accessibili, semplicemente curabili*, Suppl. n. 2 Rivista n. 2 giugno 2019, anno 20, 10-15.
54. **Nava F.A.**, 2019. La presa in carico dei consumatori di sostanze con epatite C, aspetti gestionali e organizzativi. *CCuriamo Newsletter* n. 3, 10-13.
55. **Nava F.A.**, 2019. Point of care, modello clinico operativo per l'eliminazione di HCV in Italia. Quaderno di ReAd files, Suppl. 2, n. 4, 5-9.
56. Faillace G, **Nava F.A.**, 2020. Indagine conoscitiva parlamentare in materia di politiche di prevenzione ed eliminazione di epatite C: il contributo di FeDerSerD. *Mission - Int. Quarterly Journal of Addiction*, 53, 65-68.
57. Kondili L.A., Mennini F.S., Andreoni M., Babudieri S., Gardini I., Rossi A., Russo F.P., **Nava F.A.**, Vella S., 2020. Verso una politica sanitaria di screening e linkage to care per l'eliminazione dell'infezione da epatite C in Italia. *Le Infezioni in Medicina, Special Issue* n. 2, 5-28.

Congress communications

1. De Sarro G.B., **Nava F.**, 1993. Farmacologia del dolore. *Atti Congresso Nazionale Società Italiana di Traumatologia dello Sport*, 53-66 (poster)
2. De Sarro G.B., Amendola D., **Nava F.**, Bertorelli R., De Sarro A., 1994. Effects of felbamate on two genetic models of epilepsy. *European Congress of Epileptology, Oporto, Portugal, Epilepsia*, 35, suppl. 7, 199 (poster)
3. **Nava F.**, De Sarro G.B., 1995. Animal models of epilepsy. *Behav. Pharmacol.*, 6 (Suppl. 1), 15-16 (comunicazione orale)
4. De Sarro A., Imperatore C., **Nava F.**, De Sarro G.B., 1995. Different convulsant properties of imipenem and meropenem. *Pharmacol. Res.*, 31 (Suppl.), 135 (poster)
5. De Sarro G.B., Ammendola D., Clarke G.D., Sbacchi M., **Nava F.**, De Sarro A., 1995. Anticonvulsant effects of kappa opioid agonists in DBA/2 mice. *Pharmacol. Res.*, 31 (Suppl.), 343 (poster)
6. De Sarro G.B., Ammendola D., **Nava F.**, Bertorelli R., De Sarro A., Ongini E., 1995. Effetti del felbamato su alcuni modelli di epilessia. *Atti del VI Congresso Nazionale Società Italiana di Neuroscienze*, 99, 201 (poster)
7. De Sarro G.B., **Nava F.**, Aguglia U., De Sarro A., 1996. Lamotrigine potentiates the anticonvulsant potency of some anticonvulsant in DBA/mice. *Molecular targets and cellular mechanisms of antiepileptic drugs – Jan 25-27, Genova*, 55 (poster)
8. Calapai G., Subetin L., **Nava F.**, Marciano M.C., Cuzzocrea S., Caputi A.P., 1996. Role of nitric oxide in drinking and pressor responses induced by angiotensin II: effects of water deprivation. *Fund. Clin. Pharmacol.*, 10, 169 (poster)
10. De Sarro G.B., Ammendola D., De Sarro A., Naccari F., **Nava F.**, Gareri P., Rotiroti D., 1996. Behavioural and EcoG effects of IL-4, IL-6, IL-8, and IL-10 after intraventricular injection in rat. *Fund. Clin. Pharmacol.*, 10, 184 (poster)
11. **Nava F.**, Calapai G., De Sarro G., Caputi A.P., 1996. Evident role of IL-1 on LPS induced inhibition of water intake in rat. *Fund. Clin. Pharmacol.*, 10, 206 (poster)
12. **Nava F.**, Calapai G., De Sarro A., Caputi A.P., 1996. Effects of IL-10 after intraventricular injection on drinking and exploratory behaviour in rat. *Fund. Clin. Pharmacol.*, 10, 206 (poster)
13. **Nava F.**, Calapai G., Facciola G., Cuzzocrea S., De Sarro A., Caputi A.P., 1996. Nitric oxide is involved in the thermoregulatory activity in rats. *II International Paraelios symposium nitric oxide and the cell: proliferation, differentiation and death. Paraelios (Calabria), Italy* (poster)
14. **Nava F.**, Calapai G., Facciola G., De Sarro A., Caputi A.P., 1996. Effects of disodium cromoglycate on water intake, exploratory behaviour, and rectal temperature in rat treated with endotoxin. *2nd Meeting of European Neuroscience*, 70.01 (poster)
15. Facciola G., Calapai G., Cuzzocrea S., **Nava F.**, Caputi A.P., 1996. Citochine e drinking behaviour. *Atti del V Convegno Nazionale di Giovani Cultori delle Neuroscienze*, B8 (poster)
16. **Nava F.**, Calapai G., Facciola G., Cuzzocrea S., De Sarro A., Caputi A.P., 1996. La disidratazione riduce la febbre indotta da endotossina nel ratto. *Atti del V° Convegno Nazionale di Giovani Cultori delle Neuroscienze*, D14 (poster)
17. Calapai G., **Nava F.**, Costantino G., Russo A., Caputi A.P., 1997. Involvement of dopaminergic system in the effects of inhibition of brain nitric oxide formation on voluntary ethanol intake. *Pharmacol. Res.*, 35 (Suppl.), 53 (poster)
18. Calapai G., **Nava F.**, Marciano M.C., Russo A., Caputi A.P., 1997. Nitric oxide and excitatory amino acids in voluntary ethanol intake in the rat. *Pharmacol. Res.*, 35 (Suppl.), 54 (poster)
19. De Sarro A., Naccari F., **Nava F.**, Calapai G., De Sarro G.B., 1997. Comparative convulsant properties of different xantines in genetically epilepsy prone rats. *Pharmacol. Res.*, 35 (Suppl.), 59 (poster)
20. **Nava F.**, Rotiroti D., De Sarro G.B., 1997. Involvement of intrathalamic GABAB receptors on epileptic electrocortical discharges induced by pilocarpine. *Pharmacol. Res.*, 35 (Suppl.), 62 (poster)
21. **Nava F.**, Calapai G., Marciano M.C., Facciola G., Russo A., De Sarro A., Caputi A.P., 1997. Repeated endotoxin administration produces tolerance to fever but not to inhibition of thirst in rat. *Pharmacol. Res.*, 35 (Suppl.), 70 (poster)
22. **Nava F.**, Calapai G., Facciola G., Cuzzocrea S., De Sarro A., Caputi A.P., 1997. Melatonin reduces neurotoxicity induced by lipopolysaccharide in rat. *14th International Neurotoxicology Conference*, 18 (poster)
23. **Nava F.**, Caputi A.P., Haynes, 1998. Lipopolysaccharide increases Arg-vasopressin release from suprachiasmatic nucleus slice cultures. *6th Joint Meeting of the Italian, Hungarian and Polish Pharmacological Societies*, 71 (poster)
24. **Nava F.**, Carta G., Calogero G., Caputi A.P., 1998. Alcohol abuse and its immunological interactions: a preliminary study. *IV° EASAR Congress, Rome*, 21-22 (poster)
25. Carta G., **Nava F.**, Casu M.A., Mascia S., Gessa G.L., 1998. Chronic delta9-tetrahydrocannabinol inhibits hippocampal acetylcholine release in rats. *Eur. J. Neurosci.*, 10 (Suppl. 10), 309 (poster)
26. **Nava F.**, Melis M., Caputi A.P., 1998. Effects of systemic lipopolysaccharide administration in a rat model of ethanol self-administration. *Eur. J. Neurosci.*, 10 (Suppl. 10), 310 (poster)

27. Carta G., **Nava F.**, Casu M.A., Mascia S., Gessa G.L., 1998. Il trattamento cronico con delta 9-tetraidrocannabinolo inibisce il rilascio di acetilcolina nell'ippocampo di ratto. *Atti dell'8° Congresso della Società Italiana di Psichiatria Biologica*, 212 (poster)
28. **Nava F.**, Carta G., Battasi A., Gessa G.L., 1998. Effect of single and repeated D⁹-tetrahydrocannabinol administration on memory processes in rats. *Fitoterapia, LXIX (Suppl. n° 5)*, 21 (poster)
29. Battasi A.M., **Nava F.**, Carta G., Gessa G.L., 1998. Effetti cognitivi di un trattamento cronico con delta 9-tetraidrocannabinolo. *Atti della VI^a Riunione Nazionale dei Giovani Cultori di Neuroscienze*, 98 (poster)
30. **Nava F.**, Carta G., Battasi A., Gessa G.L., 1999. Lack of tolerance to D⁹-tetrahydrocannabinol induced reduction of hippocampal acetylcholine and memory impairment. *XXIX National Congress of the Italian Pharmacological Society*, 14 (poster)
31. Battasi A., Carta G., **Nava F.**, Gessa G.L., 1999. Inhibition of hippocampal acetylcholine release after acute and repeated delta⁹-tetrahydrocannabinol. *XXIX° National Congress of the Italian Pharmacological Society*, 14 (poster)
32. Gessa G.L., Battasi A.M., Carta G., **Nava F.**, 1999. Synergy between CB₁ cannabinoid and D2 dopamine receptors in the central actions of cannabinoids. *Neurosci. Lett., Suppl. 52, S11* (poster)
33. **Nava F.**, Carta G., Satta R., Pibiri F., Gessa G.L., 2000. Interazioni fra sistema cannabinoide e dopamina. *Atti del XII Congresso Nazionale della Società di Neuropsicofarmacologia*, 79 (poster)
34. Carta G, **Nava F.**, Gessa G.L., 2000. Gli antagonisti dei recettori dopaminergici D(2) prevengono nel ratto l'azione antinocicettiva indotta dal THC. *Atti del XII° Congresso Nazionale della Società di Neuropsicofarmacologia*, 224 (poster)
35. **Nava F.**, Carta G., Gessa, G.L., 2000. Role of D(2) dopamine receptors on cannabinoid effects. *Joint Meeting British and Italian Pharmacological Societies. Birmingham 18-21 December* (poster)
36. **Nava F.**, 2001. Potenzialità terapeutiche dei cannabinoidi: rischi e benefici. *Atti del IV Congresso Nazionale della Società Italiana delle Tossicodipendenze*, 89 (poster)
37. Marino V., Caldiroli E., **Nava F.**, 2002. L'esperienza clinica del dipartimento delle Dipendenze della ASL di Varese con buprenorfina: le ricadute socio-sanitarie. *Atti della 1° Conferenza Nazionale sul Trattamento della buprenorfina della Tossicodipendenza da Oppiacei, 81-84, Palermo 20-22 giugno* (poster)
38. Gómez R., Navarro M., Ferrer B., Trigo J.M., Bilbao A., Del Arco I., Cippitelli A., **Nava F.**, Pomelli D., F. Rodriguez de Fonseca, 2002. La Hiperfagia inducida por cannabinoides se produce a través de un mecanismo periférico. *3 Reunion Nacional Sociedad Espanola de Investigacion sobre Cannabinoides, 15-16 novembre* (poster)
39. **Nava F.**, 2005. La clinica dei disturbi correlati all'uso di cocaina. *Atti del V° Congresso della Società Italiana di Tossicodipendenze, Bari, 15 maggio* (poster)
40. **Nava F.**, 2007. The neurobiological basis of poly-drugs use. *33° Congresso Nazionale della Società Italiana di Farmacologia, Cagliari, 6-9 giugno* (comunicazione orale)
41. **Nava F.**, Manzato E., Lucchini A., 2008. Gamma-hydrobutyrate reduces both withdrawal syndrome and hypercortisolism in severe abstinent alcoholics: an open randomized study vs. diazepam. *Alcohol: An International Biomedical Journal, Supplement for: Alcohol and Stress: A Framework for Future Treatment Strategies, 6-8 maggio, xxxii* (comunicazione orale)
42. **Nava F.**, Manzato E., Leonardi C., Lucchini A., 2008. Buprenorphine suppresses alcohol intake in heroin addicts with alcohol dependence through a reduction of stress response. *Alcohol: An International Biomedical Journal, Supplement for: Alcohol and Stress: A Framework for Future Treatment Strategies, 6-8 Maggio, xxvii* (poster)
43. **Nava F.**, Manzato E., Lucchini A., 2008. Chronic cannabis use does not affect the normalization of hypothalamic-pituitary-adrenal (HPA) axis induced by methadone in heroin addicts. *EPHAR 2008, 13-17 luglio, P211, 12* (poster)
44. **Nava F.**, Passudetti C., Zanusso G., Lucchini A., 2008. Cognitive-Behavioural Therapy (CBT) reduces hypothalamic-pituitary adrenal (HPA) axis hyperactivity in cocaine addicts: a comparison with interpersonal psychotherapy (IPT). *Atti del 6th International Congress of Cognitive Psychotherapy, 19-22 luglio, 84* (poster)
45. Borroni G., Bravin S., Bosticco E., Affini G.F., Gasparini G.L., Manzato E., Richini M., Torroni M., Toux M., **Nava F.**, 2010. HCV: prevalenza, fattori di rischio e risposta al trattamento in pazienti alcol dipendenti. Analisi dei dati preliminari dello studio GUM. *IV Congresso Nazionale FeDerSerD Riva del Garda, 13-16 ottobre, FeDerSerD Informa, 14, 5-7* (poster)
46. **Nava F.**, 2013. A retrospective study of the use of sodium oxybate in Northern Italy. *Alcohol and Alcoholism, 48 (Suppl. 1), i34* (comunicazione orale)
47. **Nava F.**, 2015. The misuse of opiate substitution therapy: an obstacle for the diffusion of best practices in prison, Paper session 13, *Lisbon Addiction 2015* (comunicazione orale)
48. **Nava F.**, 2015. The use and misuse of sodium oxybate in Italian alcohol dependent patients: results from the GUM Study, Rapid communication session IV (comunicazione orale)
49. Contalbrigo L., De Santis M., Montanaro M., Costa A., **Nava F.A.**, Farina L., 2016. The support of dog assisted therapy to alcohol and drug addicted inmates: the experience of Padua (north eastern Italy), IAHAIO Congress, Paris (comunicazione orale)

50. **Nava F.**, Lageder D., Marcolongo L., Dinelli E., Padovan G., 2017. The effectiveness of buprenorphine/naloxone on misuse and diversion behaviours and psychopathology in detained dual diagnosed patients: the role of the length of treatment and dosage. *Dual Disorders Addictions and Other Mental Disorders Congress, Madrid, 23-26 March* (poster)
51. **Nava F.**, Lageder D., 2017. Orienting the appropriate treatment of pain in detained drug users: indications from a retrospective study. *Lisbon Addiction 2017, Second conference on addictive behaviours and dependencies, Paper session 3, 24 October* (comunicazione orale)
52. **Nava F.**, Zuliani L., Barbon I., Branciforti I., Stroschio G., Gargiulo C., Cilia S., Sanavio E., 2017. Anger management in detained addicts for prevention of both crime and drug use: a controlled cognitive behavioural trial in an attenuate custody prison: a preliminary study., *Paper session 8, 25 October* (comunicazione orale)
53. Lageder D., Grigolin V., Marcolongo L., Conti E., Lobello S., **Nava F.A.**, 2018. A model of care of HCV elimination in prison: the preliminary report of an epidemiological survey in Padua Prison. *10° Italian Conference on AIDS and Antiviral Research (ICAR), Poster n. 128, 22-24 Maggio* (poster)
54. Rampazzo M., Minutella V., Vinti P., Galdiolo M., Costacurta M., Padovan G.B., **Nava F.A.**, 2018. A model of harm reduction program in an attenuate custody section for drug users: results and findings from the pilot experience of Padua prison. *10° Italian Conference on AIDS and Antiviral Research (ICAR), Poster n. 130, 22-24 Maggio* (poster)
55. **Nava F.A.**, Fasciani P., Cammarata L., Lucchini A., Manfredi A., Riglietta M., Taglianti G., Trotta P., 2019. The barriers for HCV treatment in Italian Drug Dependence Services (Ser.Ds): data from the SCUDO Project. *11° Italian Conference on AIDS and Antiviral Research (ICAR), Poster n. 20, 5-7 Giugno* (poster)
56. **Nava F.A.**, Chiesa A., Strepparola G., Pennisi G., Vitali R., Trevisi L., Lucchini A., 2019. The health saving costs of HCV treatment of drug users: evidence from the real practice of drug dependence services (SerDs). *10° Italian Conference on AIDS and Antiviral Research (ICAR), Poster n. 94, 5-7 Giugno* (poster)
57. **Nava F.A.** (presenting on behalf), Wiest K., Algera H., Moss L., van Velzen M., Groeneveld G.J., Heuberger J., Dahan A., Gray F., Strafford S., Dobbins R. 2019. high sustained therapeutic buprenorphine plasma levels reduce respiratory depression induced by I.v. Fentanyl. *VII° Congresso Nazionale FeDerSerD, 10 Ottobre* (comunicazone orale), *FeDerSerD Informa, 33, 22-24.*
- Nava F.A.**, Chiesa A., Strepparola C., Pennisi G., Vitali R., Lucchini A., 2019. The cost benefits for health system in treating PWIDs with chronic hepatitis C: evidence from real practice. *Lisbon Addiction 2019, 23 Ottobre* (poster)

Date, 24 Ottobre 2020

Signature

